Table 1.

Severe acute respiratory syndrome coronavirus 2‐positive inpatient cohort characteristics

Case	Age (years)	Sex	Race	BMI	Medical conditions		Symptoms at presentation	Ventilator days	Treatment
1	37	Male	Black	34.2	Asthma, DM2	Fever, cough, SOB, myalgia, HA		6	Steroids, hydroxyquinoline, empirical antibiotics
2	46	Male	Black	46.6	Asthma, DM2	Fever, cough, SOB, myalgia, HA		8	Hydroxyquinoline, empirical antibiotics
3	79	Female	White	18.5	DM2, renal transplant, bipolar disorder	Fever, cough, myalgia, diarrhoea		0*	Tocilizumab, empirical antimicrobials
4	63	Female	Black	28.2	DM2, HTN, CAD	Cough, fever		16	Sarilumab trial †

BMI, body mass index; CAD, coronary artery disease; DM2, type II diabetes; HA, headache; HTN, hypertension; SOB, shortness of breath.

^*The patient had a ‘do not intubate’ order.

^† The patient was enrolled in a phase II/III randomised, double‐blind, placebo‐controlled study assessing the efficacy and safety of sarilumab in hospitalised patients with coronavirus disease 2019. It is unknown whether the patient received sarilumab or placebo.